Literature DB >> 35085831

A likely responder approach for the analysis of randomized controlled trials.

Eugene Laska1, Carole Siegel2, Ziqiang Lin3.   

Abstract

OBJECTIVE: To further the precision medicine goal of tailoring medical treatment to individual patient characteristics by providing a method of analysis of the effect of test treatment, T, compared to a reference treatment, R, in participants in a RCT who are likely responders to T.
METHODS: Likely responders to T are individuals whose expected response at baseline exceeds a prespecified minimum. A prognostic score, the expected response predicted as a function of baseline covariates, is obtained at trial completion. It is a balancing score that can be used to match likely responders randomized to T with those randomized to R; the result is comparable treatment groups that have a common covariance distribution. Treatments are compared based on observed outcomes in this enriched sample. The approach is illustrated in a RCT comparing two treatments for opioid use disorder.
RESULTS: A standard statistical analysis of the opioid use disorder RCT found no treatment difference in the total sample. However, a subset of likely responders to T were identified and in this group, T was statistically superior to R.
CONCLUSION: The causal treatment effect of T relative to R among likely responders may be more important than the effect in the whole target population. The prognostic score function provides quantitative information to support patient specific treatment decisions regarding T furthering the goal of precision medicine.
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Causal inference; Enriched sample; Likely responders; Precision medicine; Prognostic balancing score

Mesh:

Year:  2022        PMID: 35085831      PMCID: PMC8934276          DOI: 10.1016/j.cct.2022.106688

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  37 in total

1.  Principal stratification in causal inference.

Authors:  Constantine E Frangakis; Donald B Rubin
Journal:  Biometrics       Date:  2002-03       Impact factor: 2.571

2.  Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients.

Authors:  Boris Freidlin; Richard Simon
Journal:  Clin Cancer Res       Date:  2005-11-01       Impact factor: 12.531

3.  Subgroup identification from randomized clinical trial data.

Authors:  Jared C Foster; Jeremy M G Taylor; Stephen J Ruberg
Journal:  Stat Med       Date:  2011-08-04       Impact factor: 2.373

4.  Stratification by a multivariate confounder score.

Authors:  O S Miettinen
Journal:  Am J Epidemiol       Date:  1976-12       Impact factor: 4.897

5.  Defining treatment effects: A regulatory perspective.

Authors:  Thomas Permutt
Journal:  Clin Trials       Date:  2019-02-14       Impact factor: 2.486

6.  The "Dry-Run" Analysis: A Method for Evaluating Risk Scores for Confounding Control.

Authors:  Richard Wyss; Ben B Hansen; Alan R Ellis; Joshua J Gagne; Rishi J Desai; Robert J Glynn; Til Stürmer
Journal:  Am J Epidemiol       Date:  2017-05-01       Impact factor: 4.897

7.  A two-stage Bayesian design for co-development of new drugs and companion diagnostics.

Authors:  Stella Wanjugu Karuri; Richard Simon
Journal:  Stat Med       Date:  2012-01-11       Impact factor: 2.373

8.  Treatment benefit and treatment harm rate to characterize heterogeneity in treatment effect.

Authors:  Changyu Shen; Jaesik Jeong; Xiaochun Li; Peng-Sheng Chen; Alfred Buxton
Journal:  Biometrics       Date:  2013-07-19       Impact factor: 2.571

9.  Estimating Optimal Treatment Regimes from a Classification Perspective.

Authors:  Baqun Zhang; Anastasios A Tsiatis; Marie Davidian; Min Zhang; Eric Laber
Journal:  Stat       Date:  2012-01-01

10.  Identification of predicted individual treatment effects in randomized clinical trials.

Authors:  Andrea Lamont; Michael D Lyons; Thomas Jaki; Elizabeth Stuart; Daniel J Feaster; Kukatharmini Tharmaratnam; Daniel Oberski; Hemant Ishwaran; Dawn K Wilson; M Lee Van Horn
Journal:  Stat Methods Med Res       Date:  2016-03-17       Impact factor: 3.021

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.